Creative Biolabs has announced the expansion of its custom oligosaccharide synthesis and glycan characterization services, aiming to support researchers in drug discovery, vaccine development, and biomarker studies. The company integrates chemical, enzymatic, and chemoenzymatic synthesis with comprehensive analytical platforms to provide structurally defined oligosaccharides, addressing the challenges posed by glycan complexity.
Oligosaccharides play critical roles in cell signaling, immune regulation, and disease progression, making them valuable for therapeutic and diagnostic applications. However, their structural heterogeneity complicates synthesis and characterization. Creative Biolabs' combined approach includes custom synthesis of high-purity oligosaccharides, complex glycans, tumor-associated carbohydrate antigens (TACAs), and functionalized derivatives, followed by rigorous characterization using mass spectrometry (MS), high-performance liquid chromatography (HPLC), and nuclear magnetic resonance (NMR) to determine structures, linkage patterns, and purity.
"The structural complexity of oligosaccharides continues to present significant challenges for researchers developing next-generation therapeutics," said a scientist from Creative Biolabs. "By integrating custom synthesis with comprehensive analytical characterization, we help researchers obtain structurally validated glycans that support reliable downstream studies and accelerate scientific discovery."
In one recent project, researchers required a complex glycan structure not readily available commercially. The integrated synthesis and analytical characterization enabled structural confirmation, supporting downstream applications. The company's services are designed for structural biology, glycoprotein research, biomarker discovery, immunology, and targeted drug delivery.
By combining synthesis and characterization under one platform, Creative Biolabs aims to reduce technical risks, improve reproducibility, and accelerate project progression. Researchers can explore options through the company's glycobiology platform at Creative Biolabs Glycoprotein Services.
